Clara Lebrón‐Martín

Clara Lebrón‐Martín

Auto-generated profile, based on publicly available information

Clara Lebrón‐Martín

Allergy Research Group Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina‐IBIMA Plataforma BIONAND Malaga Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2024 in Allergy
Verified
Journal Article
Open access
GHGádor Bogas Herrera
Gádor Bogas Herrera
AAAdriana Ariza
Adriana Ariza
PVPaula Vázquez‐Revuelta
Paula Vázquez‐Revuelta
MLMarina Labella
Marina Labella
RMRicardo Madrigal‐Burgaleta
Ricardo Madrigal‐Burgaleta
MTMaría J Torres
María J Torres
Background: Delabelling pathways offer confirmatory diagnosis and can prevent unnecessary second‐line therapies or drug desensitization procedures after chemotherapeutic hypersensitivity reactions (CHT‐HSRs). However, these pathways rely on risky in vivo tests. Data on whether in vitro tests could be helpful are scarce. We assessed the role of basophil activation test (BAT) in the diagnosis of HSRs to platin salts (PSs) and taxanes (TXs) in a well‐defined population featuring varied endophenotypes and severities of HSRs.Methods: We conducted a 3‐year‐long multicentric, prospective study with 121 suspected‐immediate CHT‐HSR patients. The allergy workup included clinical history (initial reaction based on Type I, cytokine release syndrome, and mixed phenotype's symptoms and if unable to fit in any of these, as “indeterminate”), skin testing (ST), and drug provocation testing (DPT), provided risk assessment was favorable. Final diagnosis classified patients as “hypersensitive,” “non‐hypersensitive,” or “inconclusive.” We performed BAT using CD63 and CD203c as activation markers in patients and controls. Patients underwent DPT regardless of BAT results to prevent bias.Results: ST positivity significantly correlated with skin involvement, Type I phenotype, cancer recurrence, and lifetime exposures before reactions. DPTs were negative in all indeterminate phenotype patients (p = .02) and those considered low‐risk, whereas they were negative in 62% moderate‐risk patients. 55% were confirmed as hypersensitive (mainly Type I reactions, p < .0001), 24% as non‐hypersensitive (mainly TXs and indeterminate phenotypes), and 21% as inconclusive. BAT showed 79% sensitivity in Type I IgE‐mediated reactions to PSs with a high correlation to ST.Conclusions: BAT is a promising tool for delabelling and endotyping CHT‐HSRs, especially Type I reactions to PSs, possibly identifying patients at risk of positive DPT. ST seems useful in confirming CHT‐HSRs, especially PS‐induced reactions, and DPT remains the gold standard, being essential even in moderate‐risk patients.

16 April 2023 in Allergy
Verified
Journal Article
Open access
JLJose Antonio Céspedes Lagos
Jose Antonio Céspedes Lagos
CLClara Lebrón‐Martín
Clara Lebrón‐Martín
RGReyes García‐Otón
Reyes García‐Otón
MDMaría Jesús Delgado
María Jesús Delgado
MMMaría del Carmen Martín-Astorga
María del Carmen Martín-Astorga
CMCristobalina Mayorga
Cristobalina Mayorga

23 January 2024 in Allergy
Verified
Journal Article
Closed access
ACAnyith Cruz‐Amaya
Anyith Cruz‐Amaya
MMMaría del Carmen Martín-Astorga
María del Carmen Martín-Astorga
CLClara Lebrón‐Martín
Clara Lebrón‐Martín
Juan L ParisJuan L Paris
Juan L Paris
JLJose Antonio Céspedes Lagos
Jose Antonio Céspedes Lagos
CMCristobalina Mayorga
Cristobalina Mayorga